To:GlobeNewswire Release Subscribers
Aug 28 at 7:00 AM
Kiadis Pharma N. V.
Published: 07:00 CEST 28-08-2018 /GlobeNewswire /Source: Kiadis Pharma N. V. / : KDS /ISIN: NL0011323407
Kiadis Pharma to attend upcoming investor conferences in September 2018
Kiadis Pharma to attend upcoming investor conferences in September 2018
Amsterdam, The Netherlands, August 28, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing a patient-specific T-cell product designed to be delivered following a haploidentical hematopoietic stem cell transplant, or HSCT, in order to support the patient's newly transplanted immune system before it becomes fully functional, today announces that it is scheduled to attend the following investor conferences in September 2018.
Goldman Sachs 8th Annual Biotech Symposium
September 7, 2018, Goldman Sachs Offices, River Court, 120 Fleet Street, London, UK
Oppenheimer Fall Summit focused on Specialty Pharma and Rare Disease
September 26-27, 2018, The Langham, 400 5th Avenue, New York, USA
KBC Securities 6th Biotech and Healthcare Conference
September 27, 2018, Convene Grand Central, 101 Park Avenue, New York, USA